Latest News

Emergency gout admission increase is ‘call to arms’


 

AT RHEUMATOLOGY 2018

It is important to reduce serum uric acid levels, Dr. Whiteman explained. “Gout occurs when serum uric acid rises and urate crystals reach their saturation point in the serum and start to crystallize out into the joints and into the tissues,” she said. “It’s a progressive disease that usually starts in one joint, but if the serum uric acid isn’t controlled then it can go on to affect a number of joints,” and cause chronic arthritis, among other potentially serious conditions, and is an independent risk factor for cardiovascular and renal disease.

“Studies across the world have shown that gout is not well looked after; patient adherence to treatment is very poor,” Dr. Whiteman said. “Among all the chronic diseases it has the lowest adherence to treatment,” she added, noting that one study showed just one-fifth of patients remained on gout medication at 1 year.

Patient education is an important part of the clinic’s services, as when people are asymptomatic and between bouts of gout, they perhaps do not realize that they still need to take their medication. Education thus needs to include talking about their diet and lifestyle, providing information on medication, and why it is important to keep their serum uric acid levels in check.

Pages

Recommended Reading

FDA approves once-daily treatment for hyperuricemia in gout
MDedge Rheumatology
Allopurinol extension trial backs treat-to-target approach in gout
MDedge Rheumatology
Febuxostat prevents early gout flares
MDedge Rheumatology
Gout incidence is intertwined with serum urate, but only up to a point
MDedge Rheumatology
FDA: Febuxostat may have increased heart-related death risk
MDedge Rheumatology
Higher water intake linked to less hyperuricemia in gout
MDedge Rheumatology
Rheumatology 911: Inside the rheumatologic emergency
MDedge Rheumatology
Health disparities in rural America: Chronic conditions
MDedge Rheumatology
Febuxostat increases cardiovascular mortality in CARES trial
MDedge Rheumatology
Allopurinol dose not escalated enough to reduce mortality
MDedge Rheumatology

Related Articles